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a  b  s  t  r  a  c  t
Sanoﬁ  Pasteur  has  developed  a  recombinant,  live-attenuated,  tetravalent  dengue  vaccine  (CYD-TDV)  that
is in  late-stage  development.  The  present  review  summarizes  the  different  steps  in  the  development  of
this dengue  vaccine,  with  a  particular  focus  on the clinical  data  from  three  efﬁcacy  trials,  which  includes
one  proof-of-concept  phase  IIb  (NCT00842530)  and  two  pivotal  phase  III efﬁcacy  trials  (NCT01373281
and NCT01374516).  Earlier  studies  showed  that  the  CYD-TDV  candidate  had a satisfactory  safety  proﬁle
and  was  immunogenic  across  the four  vaccine  serotypes  in  both  in  vitro  and  in  vivo  preclinical  tests,  as
well  as in  initial  phase  I to phase  II clinical  trials  in both  ﬂavivirus-naïve  and  seropositive  individuals.
Data  from  the  25  months  (after  the ﬁrst  injection)  active  phase  of  the two  pivotal  phase  III  efﬁcacy  studies
shows  that  CYD-TDV  (administered  at 0,  6, and  12  months)  is  efﬁcacious  against  virologically-conﬁrmed
disease (primary  endpoint)  and  has  a  good  safety  proﬁle.  Secondary  analyses  also  showed  efﬁcacy  against
all four  dengue  serotypes  and  protection  against  severe  disease  and  hospitalization.  The  end of the  active
phases in  these  studies  completes  more  than  a decade  of  development  of  CYD-TDV,  but considerable
activities  and  efforts  remain  to  address  outstanding  scientiﬁc,  clinical,  and immunological  questions,
while  preparing  for  the  introduction  and use  of  CYD-TDV.  Additional  safety  observations  were  recently
reported  from  the ﬁrst complete  year  of  hospital  phase  longer  term  surveillance  for two  phase  3 studies
and  the ﬁrst  and  second  completed  years  for one  phase  2b  study,  demonstrating  the  optimal  age  for
intervention  from  9  years.  Dengue  is  a complex  disease,  and  both  short-term  and  long-term  safety  and
efﬁcacy  will  continue  to  be addressed  by ongoing  long-term  follow-up  and  future  post-licensure  studies.
ublis©  2015  The  Authors.  P
. Introduction
The month of November 2014 saw the successful achievement
f a critical phase of an ambitious and challenging program that
ad been launched 20 years before, supported by an overall invest-
ent of more than one billion Euros, and which mobilized more
han 1000 people in a large number of countries across different
ontinents: for the ﬁrst time in human history, a robot successfully
anded on a comet. Despite difﬁculties and uncertainties, Philae and
osetta so far have achieved most of their initial goals and have
lready brought a signiﬁcant contribution to space exploration.
Abbreviations: CYD-TDV or TDV, recombinant yellow fever-17D–dengue virus,
ive, attenuated, tetravalent dengue vaccine; DENV-1–4, dengue virus serotypes
–4; PRNT50, 50% reduction dengue viral plaques as determined with the plaque-
eduction neutralization test; WHO, World Health Organization.
∗ Corresponding author at: Research and Development, Sanoﬁ Pasteur, 2 av. Pont
asteur, 69007 Lyon, France. Tel.: +33 04 37 66 98 17.
E-mail address: bruno.guy@sanoﬁpasteur.com (B. Guy).
ttp://dx.doi.org/10.1016/j.vaccine.2015.09.108
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The development of the Sanoﬁ Pasteur’s recombinant yellow
fever-17D–dengue virus, live, attenuated, tetravalent dengue vac-
cine (TDV), often referred to as the CYD dengue vaccine or CYD-TDV,
presents many similarities with the long-standing effort repre-
sented by the European Rosetta project, having started at the same
time in the mid-90s, required a similar investment, and mobi-
lized similar numbers of collaborators from multigeopgraphic and
multidisciplinary teams, within and outside the company, and for
which success could only be established at the end of development.
While it still represents a large effort necessitating the acquisition
of data in pivotal efﬁcacy trials, the present review aims to sum-
marize the different steps of this vaccine’s development, focusing
on the clinical data acquired in the last four years from three efﬁ-
cacy trials—one proof-of-concept phase IIb and two  pivotal phase
III efﬁcacy trials. It will thus update the previous reviews published
in Vaccine in 2010 and 2011 [1,2].The initial steps of the preclinical and clinical development
of CYD-TDV will be brieﬂy covered, followed by a more detailed
description and comparison of the three efﬁcacy trials, where
results of the active phase were obtained in 2012 and in 2014 [3–6].
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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eyond the observed results, these ongoing trials (now in the hospi-
al surveillance period) have generated several questions and lines
f investigations, which will be addressed. Finally, while a critical
hase has now been completed, it is important to consider what
emains to ensure implementation of the vaccine that will bring
he highest beneﬁt to human health, which will also be described.
. Early development
Previous reviews have described in detail the results of initial
nvestigations that aimed to characterize the CYD-TDV at both pre-
linical and early clinical development stages, in order to evaluate
otential risks in line with a Development Risk Management Plan
t the onset of CYD-TDV availability [1,2]. These investigations
ddressed the following points and questions, with conclusions
resented in Fig. 1:
 Genetic and phenotypic stability [7–9].
 Post-translational modiﬁcations such as glycosylation [10].
 Preclinical evaluation of immunogenicity: in vitro [11–13] and
in vivo [14–16].
 Non-clinical safety [17].
 Theoretical risks: transmission by arthropod vectors [18,19],
reversion to virulence [20], recombination with a wild
type (ﬂavi)virus [21–23], viscerotropism [11,24], sensitization/
antibody-dependent enhancement (ADE) [25].
 Initial clinical evaluation: reactogenicity/safety and immuno-
genicity, addressing both neutralizing antibody [26–33] and
T-cell responses [34–36].
These investigations demonstrated that the CYD-TDV candidate
ad satisfactory safety and immunogenicity in both in vitro and
n vivo preclinical tests, as well as in initial phase I and phase II
linical trials in both ﬂavivirus naïve and seropositive individuals.
urthermore, both humoral and cellular responses were induced in
umans against all four dengue virus serotypes (DENV-1–4) of the
accine.
These potential risks hypothesized as being associated with
hese chimeric vaccine viruses have been explored in depth. They
ave been identiﬁed based on current knowledge in the dengue
eld, and also in agreement with the European Medicines Agency
EMA) guidelines on recombinant vaccines [37]. A recently pro-
osed standardized template for a risk-beneﬁt assessment of
accines based on a yellow fever backbone is a key consideration
n the comparison of such vaccine technologies [38]. For each of
he potential risks, a risk-minimization action plan was deﬁned and
ata generated, which were subsequently reviewed with the World
ealth Organization (WHO), Pan American Health Organization,
enters for Disease Control and Prevention, key opinion leaders,
nd regulatory agencies.
. Industrial development
Scale up and industrialization were initiated very early on in the
evelopment program—in parallel with the preclinical phase and
linical phase I—to ensure that the demand for the vaccine to be
sed in clinical phase III could be met, as well as the future demand
or the licensed vaccine. The production process has been sum-
arized previously [2], and was set up to ensure a reliable and
onsistent supply of virus and cells at the industrial level.
As early as 2006, the production process was  transferred tondustrial Operations and a production facility was dedicated at
he Marcy L’Etoile site that was equipped with industrial-scale
iogenerators to produce Vero cells and virus. Brieﬂy, the four
accine viruses are produced from four virus seed lots using an(2015) 7100–7111 7101
identical manufacturing process for each serotype. Banking sys-
tems for serum-free Vero cells were established to produce master
and working viral seeds and cells, allowing reliable and consis-
tent supply of virus and cells, respectively. The vaccines and cells
are characterized and tested for safety in accordance with WHO,
European and US guidelines [39]. All the tests undertaken are
part of a control strategy designed to ensure product quality and
consistency. These included quality control speciﬁcation, product
characterization, adherence to good manufacturing practices, val-
idated manufacturing process, raw-materials testing, in-process
testing, and stability testing. The quality control speciﬁcation,
which is typical for a live, attenuated, viral vaccine, based on current
regulations and guidelines, mainly determined the purity, safety,
and potency of the vaccine [39]. Due to the use of Sanoﬁ Pas-
teur’s serum-free Vero cell banks for both cell and viral culture,
the CYD-TDV manufacturing process includes no raw materials of
animal origin; neither does the vaccine contain any preservatives,
adjuvants, or antibiotics. A proprietary stabilizer is present in the
ﬁnished product, which has been shown to have excellent stability:
accelerated stability studies have shown that the vaccine from the
phase III lots of CYD-TDV (unidose presentation) was stable up to
1 month at 25 ± 2 ◦C, and that the viral titer decreased by less than
0.5 log10 CCID50 (the 50% cell culture infective dose) after 7 days at
+37 ± 2 C. Reconstituted vaccine was found to be stable for up to
6 h at +5 ± 3 ◦C.
In 2008, 4 years before the ﬁrst results of the phase IIb clinical
trials, it was  decided to establish a new vaccine production site at
Neuville sur Saone, France, in anticipation of future vaccine needs
and to be able to minimize the vaccine-to-vaccination gap after
regulatory approval. This represented a D 300 million investment,
consistent with the continuous efforts made by the Sanoﬁ Pasteur
teams over the past 20 years toward the development of a safe and
efﬁcacious dengue vaccine. Three new dedicated facilities (utili-
ties, quality control, and production) have been built on this site
using quality by design principles, and ﬁtted with state of the art
technology equipment. The Neuville sur Saone production facilities
scales up the Marcy l’Etoile facility and can produce up to 100 mil-
lion doses per year of vaccine virus (drug substance, packaged in
monodose or multidose vials). The new site has gone through the
qualiﬁcation and validation steps, and consistent lots have already
been produced at this site that will ensure the availability of the
vaccine on an industrial scale over the coming years.
Another important Sanoﬁ Pasteur site, in Val de Reuil, France,
is also involved in the production of CYD-TDV. Here, the vaccine
is formulated, ﬁlled, lyophilized, and packaged before release. The
ﬁnal product can then be shipped from Val de Reuil to all over the
world (through distribution facilities).
4. Recent clinical development: phase IIb (CYD23) and
phase III (CYD14 and CYD15) efﬁcacy trials
The clinical development of CYD-TDV has complied with the
International Conference on Harmonization guidance for indus-
try, as well as the US Food and Drug Administration and European
Medicines Agency guidelines for new vaccines, and the WHO  Tech-
nical Report Series 932 guidelines for the production and quality
control of live candidate tetravalent dengue virus vaccines [39].
This required consideration of speciﬁc development challenges
(Fig. 1), in addition to the lack of a predictive immunocompetent
animal disease model. These challenges include but are not limited
to: (i) the need to induce an adequate immune response to all four
serotypes; (ii) the current absence of a correlate and threshold of
protection, and thus the need to demonstrate clinical efﬁcacy; (iii)
the need to demonstrate long-term safety; (iv) the potential risks
after vaccination of sensitization to severe dengue infection and of
7102 B. Guy et al. / Vaccine 33 (2015) 7100–7111
Fig. 1. The preclinical and early clinical development of the CYD-TDV. Investigations addressed the genetic and phenotypic stability of the CYD dengue viruses, their post-
translational modiﬁcations, and their in vitro and in vivo immunogenicity in primary/transformed cells and in monkeys. Non-clinical safety (NCS) was assessed in mice,
monkeys, and rabbits. Theoretical risks were assessed in various in vitro and in vivo models, and the B and T cell responses in phase I and phase II trials. Abbreviations: ADE,
antibody-dependent enhancement; CMI, cell-mediated immunity; CYD, chimeric yellow fever dengue; CYD-1–4, dengue vaccine serotypes 1–4; DART, developmental and
reproductive toxicology; DC-SIGN, dendritic cell-speciﬁc intercellular adhesion molecule-3-grabbing non-integrin, also known as CD209; DENV 1–4, dengue virus serotypes
1–4;  IFN, interferon; IV, intravenous; m-DCs, monocyte-derived dendritic cells; NS3, non-structural antigens; PRNT, plaque-reduction neutralization test; wt, wild type; YFD
17D,  yellow fever virus strain 17D.
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cute viscerotropic disease and neurotropic disease, which are very
are serious adverse events after vaccination with the yellow fever
irus (YFV)-17D vaccine; and (v) the need to comply with genet-
cally modiﬁed organisms regulations. Additional complexity for
linical development included differential background ﬂavivirus
eroprevalence rates between regions, necessitating that trials be
onducted in parallel at numerous sites across different countries
nd in different continents. In this regard, an additional challenge
as to ensure that there was appropriate clinical trial infrastructure
n place across these various sites.
As mentioned previously, the CYD-TDV candidate had a satisfac-
ory safety proﬁle and good immunogenicity in initial phase I and
hase II trials, and in subsequent phase III trials [4,5,32]. These trials
ere conducted over ten years on several continents in children,
dolescents and adults with a diverse ﬂavivirus infection and vac-
ination history, as a prelude to the efﬁcacy trials. Overall, nearly
0,000 participants have received at least one dose of the CYD-
DV, and in compliance with the WHO  guidelines, at each phase
f clinical development many participants have been and are still
eing followed up on the long-term (3–5 years), in order to monitor
ong-term safety including for potential severe dengue.
As part of the clinical development of the vaccine, three efﬁcacy
rials were undertaken, the results from which have been published
n the past two years. These included a proof-of-concept phase IIb
fﬁcacy trial in Thailand [3], and two pivotal phase III efﬁcacy tri-
ls in Asia [4] and Latin America [5]. Indeed, the ﬁrst priority was
o develop the vaccine in endemic countries of Asia-Paciﬁc, Latin
merica, and the Caribbean to address the unmet medical need in
hese regions. The main results of these three trials are presented
n Table 1.
.1. First proof-of-concept efﬁcacy study in Thailand: CYD23
hase IIb (NCT00842530)
The proof-of-concept, phase IIb clinical efﬁcacy study was  an
bserver-masked, randomized, controlled, single-center trial in
ealthy Thai schoolchildren aged 4–11 years, who  were randomly
ssigned (2:1) to receive three injections of CYD-TDV or control
rabies vaccine or placebo) at 0, 6, and 12 months in one high inci-
ence area in Ratchaburi, Thailand [3]. Participants were actively
ollowed up until 25 months (active phase). All acute febrile ill-
esses were tested for dengue, and viremia was  conﬁrmed by
erotype-speciﬁc reverse transcriptase polymerase chain reaction
RT-PCR) and non-structural protein 1 enzyme-linked immunosor-
ent assay. The primary objective was to assess the protective
fﬁcacy against virologically-conﬁrmed, symptomatic dengue, irre-
pective of severity or serotype occurring at least 1 month after
he third injection and up to the end of the active phase (per-
rotocol analysis). A total of 4002 participants were assigned to
accine (n = 2669) or control (n = 1333), with 3673 participants
verall included in the primary analysis (vaccine, n = 2452; control,
 = 1221). During the study, 134 cases of virologically conﬁrmed
engue occurred. The incidence of dengue disease was high in
he trial (dominated by serotype 2), and the more than expected
umber of cases enabled endpoints that would have otherwise not
een possible to consider, including serotype-speciﬁc efﬁcacy, to be
ssessed. A similar situation (involving all 4 serotypes) was  encoun-
ered in the two subsequent phase III trials (CYD14 and CYD15
tudies; see below).
In the CYD23 study, vaccine efﬁcacy according to the primary
ndpoint was 30.2% (95% conﬁdence interval [CI]: −13.4 to 56.6),
ut differed by serotype. In the intent-to-treat population (i.e. all
articipants who received ≥1 injection, analysis performed from
he ﬁrst dose, month 0–25), the efﬁcacy observed for DENV-1 was
1.2% (95% CI: 17.4–82.1), 81.9% (95% CI: 38.8–95.8) for DENV-
, and 90.0% (95% CI: 10.6–99.8) for DENV-4. However, for the(2015) 7100–7111 7103
serotype 2, the predominant serotype, efﬁcacy was only 3.5% (95%
CI: −59.8 to 40.5). The lack of observed efﬁcacy against DENV-2
occurred despite satisfactory immunogenicity as determined by the
plaque-reduction neutralization test (PRNT50) levels 28 days after
the third dose, which were at least similar to the other serotypes
(Table 1).
The dengue vaccine was well tolerated, with no safety signals
after 2 years of active follow-up after the ﬁrst dose. The subsequent
hospital-phase surveillance for the phase IIb study (the CYD57
study) continues until 2016. For the ﬁrst time, these data showed
that a vaccine against dengue was feasible, but it raised several
important questions; in particular, the link between PRNT50 levels
and protection, and the importance of varying serotype-speciﬁc
efﬁcacy. Both topics will be addressed later in this review. One
has also to consider some differences between the phase IIb and
Phase III efﬁcacy trials (Table 1): the phase IIb was  a single center
study, the deﬁnition of acute febrile illness was slightly different,
and serotype 2 was the dominant circulating serotype in the study.
4.2. Pivotal phase III efﬁcacy studies in Asia and Latin America:
CYD14 (NCT01373281) and CYD15 (NCT01374516)
The active phases of two, pivotal, phase III efﬁcacy studies were
undertaken in children aged 2–14 years in Asia [4], and in children
and adolescents aged 9–16 years in Central and South America,
using consistency lots at ﬁnal industrial scale [5]. Each trial included
ﬁve endemic countries (involving 11 sites in Asia and 22 sites
in Latin America) and, as in CYD23, examined the efﬁcacy of a
three-dose schedule (0, 6, and 12 months) of CYD-TDV to reduce
symptomatic, virologically-conﬁrmed dengue during a period of 12
months starting 28 days after the third dose (Fig. 2). In both trials,
the primary endpoint was for the lower bound of the 95% conﬁ-
dence interval (CI) of vaccine efﬁcacy to be greater than 25% (versus
0% in the previous Phase IIb). The active phase of these two trials
has now been completed, providing efﬁcacy and safety results from
the ﬁrst 25 months following the initial immunization (Table 1).
In the Asian trial (CYD14), efﬁcacy against virologically-
conﬁrmed dengue was 56.5% (95% CI: 43.8–66.4) in the per protocol
group, irrespective of disease severity against any serotype. Sim-
ilarly, in the Central and South American trial (CYD15), overall
efﬁcacy against virologically-conﬁrmed dengue was  60.8% (95% CI:
52.0–68.0). Thus, both trials successfully met  their primary end-
point (i.e. lower limit of the 95% CI for efﬁcacy was >25%) with
comparable overall efﬁcacy between the two  studies. Secondary
descriptive analyses in the Asian study showed that all four dengue
serotypes contributed to the overall efﬁcacy during the active
phase, although the efﬁcacy against serotype 2 was inconclusive,
as the lower limit of the 95% CI for vaccine efﬁcacy included zero in
the per protocol analysis. In the Central and South American trial,
efﬁcacy was highest against serotype 4 and lowest for serotype 2,
but was conclusive against all four serotypes (i.e. lower limit of the
95% CI of vaccine efﬁcacy was above zero in both the per-protocol
and the intent-to-treat analyses). To provide a broader perspective,
pooled efﬁcacy analyses for both these trials demonstrated con-
clusive efﬁcacy against all four serotypes [40]. The varying levels
of efﬁcacy against the four serotypes further conﬁrm the impor-
tance of having sufﬁciently large ﬁeld efﬁcacy trials to capture an
adequate number of cases with which to address such secondary
endpoints, or to demonstrate protection against hospitalization and
severe disease (see below).
During the active phase, both trials showed higher efﬁcacy
against severe disease and hospitalization for dengue, as well as
trends toward reduced symptomatology from dengue after vac-
cination (in CYD14, 56.5% overall efﬁcacy against dengue disease
vs 67.2% against hospitalization and 80.0% against dengue hem-
orrhagic fever; in CYD15, 60.8% overall efﬁcacy against dengue
7104 B. Guy et al. / Vaccine 33 (2015) 7100–7111
Table 1
Design and main results of the active phase of Phase IIb and pivotal Phase III efﬁcacy studies with CYD-TDV.
CYD23 (NCT00842530) [3] CYD14 (NCT01373281) [4] CYD15 (NCT01374516) [5]
Study design
Primary objective To assess the efﬁcacy of CYD dengue vaccine after 3 vaccine doses at 0, 6, 12 months in preventing symptomatic virologically-conﬁrmed
dengue cases (>28 days PD3), regardless of severity, due to any of the 4 serotypes
Age  at inclusion (years) 4–11 2–14 9–16
Acute febrile illness Fever for at least 1 day
(temperature ≥37.5 ◦C
measured at least twice at least
4 h apart)
Temperature ≥38 ◦C on at least 2 consecutive days
Virological conﬁrmation Dengue RT-PCR and/or dengue
NS1 ELISA Ag test
Dengue RT-PCR and/or dengue NS1 ELISA Ag test
Simplexa dengue RT-PCR used for ST identiﬁcation
Per  protocol set Per protocol set for efﬁcacy (PPSE) included all participants who  received 3 injections and who  were compliant with the protocol, and
was  used to assess the primary objective
Power 80% 90% 90%
Lower limit 95% CI VE >0% >25% >25%
Assumed incidence 1.3% 1.3% 0.64%
Sample size
(vaccinees/Placebos: 2/1)
4002 10,275 20,869
Countries Thailand (1 site) Thailand, Philippines, Vietnam,
Indonesia, Malaysia (11 sites)
Brazil, Mexico, Honduras,
Columbia, Puerto Rico (22
sites)
Epidemiology
Observed attack rate 2.6% 4.7% 2.9%
Cases 134 595 662
Serotype distribution ST1: 29%; ST2: 43%; ST3: 18%;
ST4: 8%; Unserotyped: 1%
ST1: 39%; ST2: 23%; ST3: 13%;
ST4: 22%; Unserotyped: 3%
ST1: 28%; ST2: 21%; ST3: 27%;
ST4: 21%; Unserotyped: 3%
Per  protocol VE (95% CI)a
Any serotype 30.2% (−13.4, 56.6) 56.5% (43.8, 66.4) 60.8% (52.0, 68.0)
Serotype-speciﬁc ST1:  55.3%
(−22, 83.9)
ST2: 15.6%
(−58, 53.6)
ST1: 50.0%
(24.6, 66.8)
ST2: 35.0%
(−9.2, 61)
ST1: 50.3%
(29.1, 65.2)
ST2: 42.3% (14,
61.1)
ST3:  75.1%
(−375, 99.6)
ST4: 100%
(24.3, 100)
ST3: 78.4%
(52.9, 90.8)
ST4: 75.3%
(54.5, 87)
ST3: 74.0%
(61.9, 82.4)
ST4: 77.7%
(60.2, 88)
ITT  VE (95% CI)b
Any serotype 34.9% (6.7, 54.3) 54.8% (46.8, 61.7) 64.7% (58.7, 69.8)
Serotype-speciﬁc ST1:  61.2%
(17.4, 82.1)
ST2: 3.5% (−58,
40.5)
ST1: 54.5%
(40.9, 64.9)
ST2: 34.70%
(10.4, 52.3)
ST1: 54.8%
(40.2, 65.9)
ST2: 50.2%
(31.8, 63.6)
ST3:  81.9%
(38.8, 95.8)
ST4: 90% (10.6,
99.8)
ST3: 65.2%
(43.3, 78.9)
ST4: 72.4%
(58.8, 81.7)
ST3: 74.2%
(63.9, 81.7)
ST4: 80.9%
(70.9, 87.7)
VE  (95% CI)
Severe diseasec 49.9% (−590.6, 96.4) 70.0% (35.7, 86.6 95.5% (68.8, 99.9)
DHFd 49.9% (−590.6, 96.4) 80.0% (52.7, 92.4) 95.0% (64.9, 99.9)
Hospitalization 46.8% (9.3, 68.7) 67.2% (50.3, 78.6) 80.3% (64.7, 89.5)
Immunogenicity/PRNT GMTs (95% CI)
Baseline ST1: 42.8 (30.7,
59.6)
ST2: 56.8 (40.3,
80.1)
ST1: 38.3 (33.8,
43.5)
ST2: 55.3 (48.7,
62.9)
ST1: 128 (112,
145)
ST2: 138 (123,
156)
ST3:  31.5 (24.2,
41.0)
ST4: 28.1 (21.7,
36.4)
ST3: 40.1 (35.6,
45.1)
ST4: 25.3 (22.9,
28.0)
ST3: 121 (108,
136)
ST4: 43.6 (39.6,
48.0)
28d  Post Dose 3 ST1: 155 (116,
207)
ST2: 358 (283,
453)
ST1: 166 (150,
183)
ST2: 355 (327,
386)
ST1: 395 (353,
441)
ST2: 574 (528,
624)
ST3:  351 (289,
428)
ST4: 151 (128,
178)
ST3: 207 (189,
226)
ST4: 151 (141,
162)
ST3: 508 (465,
555)
ST4: 241 (226;
258)
Abbreviations: Ag, antigen; CI, conﬁdence interval; DHF, dengue hemorrhagic fever; ELISA, enzyme-linked immunosorbant assay; GMTs, geometric mean titers; NS1, non-
structural antigen 1; PRNT, plaque-reduction neutralization test; RT-PCR, reverse transcriptase polymerase chain reaction; ST, serotype; VE, vaccine efﬁcacy. Bold numbers
are  point estimates.
a Per protocol (PP) analysis: assessment of protective efﬁcacy against virologically conﬁrmed, symptomatic dengue, irrespective of severity or serotype, occurring 1 month
after  the third injection and through to the end of the 25-month active phase (see Fig. 2).
b Intent-to-treat (ITT) analysis: assessment of protective efﬁcacy against virologically conﬁrmed, symptomatic dengue, irrespective of severity or serotype from the ﬁrst
injection through to the end of the 25-month active phase (see Fig. 2).
c According to the independent data monitoring committee (IDMC) deﬁnition. Assessment made by the investigators. Cases classiﬁed as severe based on predeﬁned criteria
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pnd  following a medical chart review (criteria extracted from SEARO 2011, WHO  199
d According to the WHO  1997 classiﬁcation [89]. Cases classiﬁed by statistical pro
ot  include organ dysfunction.
isease vs 80.3% against hospitalization and 95.5% against dengue
emorrhagic fever (Table 1). Given the impact of severe disease and
ospitalization for dengue on the public health systems in endemic
ountries, these results are pertinent from a public health perspec-
ive.
One important observation in the CYD14 trial was  that efﬁcacy
ncreased with age [4]. In addition, in both CYD14 and CYD15 trials,
rior exposure to dengue was identiﬁed as an important covariateWHO  2009 classiﬁcations) [89,90]. Organ dysfunction is also included in the criteria.
. Cases without ≥2 days of fever are excluded from the WHO  deﬁnition. Criteria do
for efﬁcacy, which was higher in participants who were dengue
seropositive at baseline compared with those who  were seronega-
tive. The increase in age presumably reﬂects accumulative exposure
to dengue, and age may  therefore represent a surrogate for seropos-
itivity. Nevertheless, one cannot clearly discriminate whether age
is a confounding factor or can have an independent impact (see Sec-
tion 4.3). Moreover, our observations on the impact of serostatus at
baseline come from a more limited sample size (immunogenicity
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Fig. 2. Design and timelines of the two pivotal phase III efﬁcacy studies; the results are presented in Table 1. Trials were conducted in Asia (CYD14) and Latin America (CYD15),
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pn  ﬁve countries for each. Three injections were administered 6 months apart in 2–1
YD15  trial. Per protocol (PP) and intent-to-treat (ITT) analyses were performed dur
he  4-year hospital phase. Abbreviations: mo,  months; VCD, virologically conﬁrmed
ubset of volunteers). Meta-analysis of efﬁcacy was  also performed
or the active phase of CYD14 and CYD15, and further analyses of
ospital phase surveillance data (see below) prompted a focus for
he pooled analysis on an age cut-point of ≥9 years, which was  also
he lower age of participants enrolled in CYD15 [41]. Vaccine efﬁ-
acy against virologically conﬁrmed dengue (VCD) of any severity
ue to all serotypes in the pooled analyses for participants aged ≥9
ears in the active phase was 65.6% (95% CI: 60.7; 69.9). Pooled vac-
ine efﬁcacy (VE) for seronegative individuals aged ≥9 years was
2.5% (95% CI: 5.9; 76.1). VE was also conﬁrmed in individuals who
ere seropositive at baseline: 81.9 (95% CI: 67.2; 90.0). Pooled VE
gainst hospitalization for dengue among participants aged ≥9 was
0.8% (95% CI, 70.1–87.7). In the same population, pooled VE for
evere dengue, as deﬁned according to the criteria of the indepen-
ent data monitoring committee, was 93.2% (95% CI, 77.3–98.0) and
he vaccine efﬁcacy against DHF, as deﬁned according to the WHO
riteria, was 92.9% (95% CI, 76.1–97.9) [41].
In both trials, the safety proﬁle for CYD-TDV was similar
o placebo during the 25-month active phase, with no marked
ifferences in the rates of adverse events, in agreement with
revious clinical trials [3,30,31]. This safety proﬁle linked the CYD-
V technology is a key clinical attribute when referring to the
revious failure of previous empirically attenuated live denguer-old children in the CYD14 trial, and 9–16-year-old children and adolescents in the
e 25-month active phase, which is now completed. Both trials are halfway through
ue; VE, vaccine efﬁcacy.
vaccine candidates, which evidenced substantial reactogenicity.
The frequencies of serious adverse events were similar between
the vaccine and control groups, and the events were consistent
with medical conditions in this age group. Infections and injuries
were the most commonly reported serious adverse events, but
were unrelated to vaccination. No short-term or long-term safety
issues potentially linked to sensitization were observed during the
active phase, and no severe immediate hypersensitivity or aller-
gic reactions were related to vaccination. Moreover, no cases of
acute viscerotropic or neurotropic diseases were recorded, and no
vaccine-related deaths were reported.
Beyond the active phase of surveillance during the phase 3
efﬁcacy trials, the clinical development program for the CYD-TDV
candidate vaccine includes a four-year long term follow-up (LTFU)
phase, i.e. the Hospital Phase, starting 13 months after the third
vaccine administration and ending ﬁve years after completion of
the vaccination schedule to assess safety, in line with the WHO
guidelines. Hospitalization for acute fever is recorded during study
contacts, and by self-reporting and surveillance of the hospital
networks.
During the ﬁrst year of the LFTU in the multicentric Asian trial
CYD14, the relative risk of hospitalization for virologically con-
ﬁrmed dengue in the vaccine group as compared with the control
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roup was 1.04 (95% conﬁdence interval [CI], 0.52–2.19) [41]. Pre-
lanned analyses showed that the risk was observed in younger
hildren, particularly in the youngest age group analyzed, 2–5
ears. This shift in Relative Risk (RR) for hospitalized VCD directed
s to address it separately in populations below and above 9 years;
n this regard, no issue was seen in ≥9 years in the ﬁrst year of
ong term follow up in CYD14 and in the ﬁrst two years in CYD57
follow up of the CYD23 Phase IIb trial), and similarly no issue was
een in CYD15 in pre-planned analysis ≥9 years. When considering
ooled relative risks (RRs) during the ﬁrst year of LTFU of CYD14,
YD15 and CYD57, RRs were 0.84 (95% CI: 0.56; 1.24), 1.58 (95%
I: 0.83; 3.02) and 0.50 (95% CI: 0.29; 0.86), for all participants,
nd those aged <9 and ≥9 years, respectively. Importantly, there
ere no clinically important differences in the frequencies of vari-
us signs and symptoms in the hospitalized participants were seen
etween the efﬁcacy surveillance phase and the long-term follow-
p phase in any of the studies or between the vaccine and control
roups. Cumulative RRs (active phase and ﬁrst year of LTFU) were:
YD14: 0.46 (95% CI: 0.32; 0.65), CYD15: 0.28 (95% CI: 0.18; 0.44)
nd CYD23/57: 0.66 (95% CI: 0.43; 1.02). In totality, these analy-
es suggested that the optimal age for intervention is from 9 years
iven the observed favorable clinical proﬁle with higher efﬁcacy for
reventing VCD and an acceptable post-vaccination safety proﬁle
or individuals aged ≥9 years.
These results for both the active period and the ﬁrst years of
he hospital phase, which include data from 10 countries, different
opulations (age and ethnicity), and different dengue seasons (with
ifferent circulating serotypes and levels of endemicity), provide a
onsistent picture of the efﬁcacy and safety of CYD-TDV.
.3. Questions, investigations and next steps
Overall, the phase IIb and phase III results identiﬁed important
eterminants of efﬁcacy with the CYD-TDV, in particular the vary-
ng serotype-speciﬁc efﬁcacy, the importance of dengue baseline
re-immunity, and the potential importance of age as a surrogate
or prior exposure. In addition, age could also reﬂect some imma-
urity at both the immunological and physiological levels [42,43].
hese aspects have been and are still being addressed through
nvestigations carried out in-house and/or through external collab-
rations [40]. Firstly, the efﬁcacy trials showed higher protection
gainst serotypes 3 and 4 than against serotypes 1 and 2, while
imilar neutralization geometric mean titer (GMT) values were
bserved for all four serotypes in the Vero cell-based PRNT50 assay.
ost-study investigations to understand this result included a broad
rray of analytical and experimental methods in four areas: host
nd immunity, virus, vaccine and vector [44,45]. To date, results
uggest that despite the presence of key epitopes on the vaccine
iruses, qualitative differences exist in responses against the dif-
erent serotypes in naïve volunteers, although it is necessary to
urther conﬁrm the results obtained in a larger number of sera.
ngoing, clinical, long-term follow-up and investigations should
rovide additional critical elements. A human challenge model,
uch as the one developed by the Walter Reed Army Institute of
esearch (WRAIR) could also provide some additional answers to
ome of these aspects [46]. Preliminary results from these inves-
igations and the additional remaining questions are presented in
he following points and summarized in Fig. 3:
) Host and immunity What is the impact of the quantitative response against each
serotype with regard to protection? Exploratory analyses using
logistic regression suggest a relationship between the probabil-
ity of disease and PRNT titers [44]. Some studies also suggest that(2015) 7100–7111
levels required for protection may  differ according to serotypes
[47,48].
- Besides the WHO  recommended PRNT50 used in our studies [49],
should alternative assays be used in replacement of, or in addition
to this assay [50–52], which could bring additional informa-
tion on the quality of vaccine-induced immunity? In this regard,
are there qualitative differences in the responses induced by
each CYD-TDV serotype? The speciﬁcity of the vaccine-induced
antibodies was assessed using sera from a completed clinical
trial (NCT01134263) in ﬂavivirus-seronegative participants at
baseline. Sera were depleted using virus-coated beads, and neu-
tralization was assessed before and after depletion in a ﬂow
cytometry-based assay using U937-DC SIGN+ cells [45,52]. These
experiments showed that in this dengue-naïve population, CYD-
TDV vaccination elicited mostly homotypic responses against
only a few serotypes (e.g. DENV-4), while responses against
the remaining serotypes were in majority heterotypic. On the
other hand, it was  shown using the same assays that vaccination
in dengue-primed individuals triggered a qualitatively different
immune response, with no more dominance of responses against
DENV-4 (see below).
- Alternatively, or in addition, could lower protection be
linked to the induction of potentially enhancing responses
against some particular serotypes? To address a potential
sensitization/antibody-dependent enhancement (ADE) issue for
lower efﬁcacy serotypes, the balance between neutralizing anti-
bodies and potentially enhancing ones were also assessed for each
serotype in an in vitro assay using FcR+ transfected CV1 cells
[50,53]. It was shown in particular that vaccine-induced anti-
DENV-2 and anti-DENV-1 responses were not lower than against
the other two  serotypes in this assay.
- Why  does dengue serostatus at baseline inﬂuence subsequent
vaccine efﬁcacy? It was shown in the CYD14 and CYD15 stud-
ies that the baseline dengue serological status was an important
covariate for efﬁcacy (see above), and therefore, it was  important
to also characterize the type of immunity present in sera from vac-
cinated participants who  were dengue-seropositive at baseline.
It was  previously observed that higher PRNT50 responses were
induced after vaccination in ﬂavivirus seropositive than seroneg-
ative participants [28–30]. Subsequently, using depletion studies
as mentioned above, it was  observed in the sera from seropositive
participants at baseline that a higher and broader cross-reactive
response was  present against all four serotypes after vaccina-
tion [45]. Cross-protection is induced during a certain period
after natural wild-type dengue infection [54–59], which is further
increased after secondary infection [60]. This can be linked to the
induction of higher levels and quality of cross-reactive neutraliz-
ing antibodies [61–66]. Should vaccination in dengue seropositive
participants at baseline act as an attenuated secondary wild-type
infection, it may  thus provide a better subsequent protection,
which is in agreement with observations from the CYD14 and
CYD15 trials.
- In addition to serostatus at baseline, could age play an addi-
tional role? Younger children may  mount a less effective immune
response, and/or be more susceptible to infection and severe dis-
ease because of some vascular physiological differences (ongoing
development of the capillary system) [42,43,67–70]. This could
also play a role in the observations made during the ﬁrst year of
hospital phase in the younger CYD14 population [41]. In addition,
age is likely to act as a surrogate of prior exposure and seropos-
itivity, which could explain why age-related variance in efﬁcacy
was seen in the CYD14 study.- What is the role of cell-mediated immunity? T-cell responses
induced by wild-type dengue infection can play a positive role in
protection, depending on their proﬁle and speciﬁcity (for a review
see [71–74]). As mentioned previously, CYD-TDV induces T-cell
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Fig. 3. Investigations carried out after the phase IIb and phase III trials (still ongoing). These investigations addressed the potential role of the vaccine, wild type virus and host
immune response in the observed results. The role of the mosquito vector and force of infection have not been addressed yet. Abbreviations: Ab, antibody; CMI, cell-mediated
i bs, mo
-mmunity; CYD, chimeric yellow fever dengue; HLA, human leukocyte antigen; mA
responses against dengue structural antigens in seronegative
individuals, while in seropositives, vaccination also recalls T-cell
responses against dengue non-structural antigens (NS3) [35]. In
this regard, what is the role of T-cell responses induced or recalled
after CYD-TDV with respect to protection against infection and
symptomatic disease, in both seropositive or seronegative partic-
ipants? Also, might there be a role for human leukocyte antigen
(HLA) or other genetic factors [75,76]?
 What is the position regarding longer term safety and efﬁcacy?
Results have been obtained during the active phase, and, as stated
previously, it has been observed that transient cross-protection
is induced after wild-type infection [54–60]. How can it apply to
vaccination, in particular, in those who are seronegative at base-
line? Data acquired during the ongoing hospital phase has already
brought additional information regarding both efﬁcacy and safety
in the different populations (according to age and serostatus), and
will give an indication whether or not a booster dose is required
in certain populations. Ongoing long-term clinical follow-up and
investigations will inform in particular on the evolution of the
imbalance in VCD observed in the ﬁrst year of the hospital phase
in vaccinees aged <9 years. Several plausible interrelated bio-
logic hypotheses could explain this imbalance, involving waning
immunity, age/serostatus and temporal clustering of infection in
vaccinees, as proposed in Hadinegoro [41]. Statistical and clinicalnoclonal antibodies; PRNT, plaque-reduction neutralization test; wt, wild type.
investigations are ongoing to explore these hypotheses. The risk
management plan (RMP) established upfront will also be impor-
tant to assess the beneﬁt risk proﬁle of the vaccine over time (see
below).
ii) The virus
- Could some immune escape be responsible for the lower observed
efﬁcacy despite similar responses against parental strains? It was
observed that antigenic diversity between parental vaccine virus
and wild-type isolates obtained in the CYD23 study—including
DENV-2—did not impact neutralization in a Vero cell-based
PRNT50 assay using serum from either CYD-TDV or placebo recip-
ients [45]. This is in agreement with a previous study showing the
broad neutralization of a large range of clades and genotypes for
each given serotype when using sera obtained after tetravalent
vaccination [77].
- Alternatively, a potential increased ﬁtness of these wild-type
strains (unique clade [78]) could require higher serological
responses for protection. Sequence analysis of viruses responsi-
ble for cases in the CYD14 and CYD15 studies is ongoing, which
will bring more information on the potential link between the
level of protection and circulating clades/genotypes within each
serotype.
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Fig. 4. Major steps of CYD-TDV development, from upstream research to vaccine introduction, covering more than 15 years. Some activities have been performed sequentially
(e.g.  initial preclinical studies followed by phase I clinical development), while some others have been launched in parallel (e.g. late clinical development and the building
o e IIIb a
a
-
i
-
-
-f  facilities for vaccine production, as well as CTD preparation). Post-licensure phas
fter  vaccine introduction. Abbreviations: CTD, common technical document.
 One has also to consider that a complex interplay may  exist
between the nature of host dengue serostatus and the nature of
the circulating clades regarding the outcome of disease [79].
ii) The vaccine
 Are there differences in the ability of each CYD-TDV serotype to be
infectious in vivo and its ability to trigger an effective response?
Beyond the initial study that showed protection in monkeys [15],
it was recently demonstrated that the DENV-2 vaccine serotype
(CYD-2) could confer some protection against a more stringent
DENV-2 challenge in monkeys, conﬁrming its immunogenicity
in vivo [80].
 If serotype-speciﬁc responses vary according to serotypes, is
it linked to differences in serotype-speciﬁc epitope presenta-
tion of the vaccine dengue serotypes? Despite differences in
homotypic responses in naïve volunteers, it was observed using
human monoclonal antibodies that key serotype-speciﬁc qua-
ternary epitopes [81–83] were present and recognized on the
corresponding DENV-1, 2, and 3 vaccine serotypes (CYD-1, -2,
and -3) (monoclonal antibodies were not available for DENV-4),
while cross-reactive anti-rE DI-II or DIII monoclonal antibodies
recognized all four CYD dengue vaccine serotypes [45]. The use
of additional monoclonal antibodies, such as those targeting the
envelope dimer epitope (EDE antibody) [84], could also provide
additional important information.
 Can the amount of administered vaccine viruses impact sub-
sequent immune responses? Prior retrospective clinical data
suggest a relationship between vaccine potency (the 50% cellnd phase IV studies will keep documenting the effectiveness and long-term safety
culture infective dose; CCID50) and neutralization [44]. It remains
to be determined whether or not higher doses of live attenuated
dengue vaccines could translate to incrementally higher clinical
efﬁcacy.
iv) The vector
- Given that efﬁcacy results were consistent between the CYD14
and CYD15 trials, despite being conducted in different geographic
areas and during different dengue seasons (epidemic or endemic
situations), it would suggest that different forces of infection
may  not play a major role in the observed differences between
serotypes. One point, however, which needs to be addressed
further—linked with host immunity—is whether or not asymp-
tomatic infection in those vaccinated results in sufﬁcient viremia
to allow transmission of dengue virus to uninfected mosquitoes
[85]. This would impact the ability of the vaccine to provide indi-
rect protection, and warrants further investigations.
5. Next steps: how can the beneﬁt of the CYD-TDV be
maximized?
The development and production of a safe and efﬁcacious vac-
cine are the ﬁrst steps toward providing protection to populations
at risk from dengue. In this regard, it will be important to deﬁne
the populations which will beneﬁt the most from the CYD-TDV. In
addition, a number of other challenges—including epidemiological,
economic, regulatory, and logistical—must also be met  to ensure
the successful introduction of the vaccine in any region [2].
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One of the main challenges is determining the true burden of
engue disease to judge the optimal point of intervention in a coun-
ry vaccination program. Estimates of disease incidence and burden
hat rely solely on the number of reported cases will inevitably
nderestimate the magnitude of the problem. Improved surveil-
ance systems would improve the quantiﬁcation of the medical
alue of dengue vaccination programs. The epidemiology of dengue
aries considerably, both geographically and temporally, which
ay  impact the way the vaccine would be used in each coun-
ry. Computational modeling will play a substantial role collating
ultiple parameters with which to assess the impact of vaccina-
ion on disease burden at a population level and therefore assist
ational organizations identify the optimal programs and catch-up
ohorts for the maximal public health beneﬁt. In this regard, param-
ters related to vaccine efﬁcacy and levels of dengue transmission
ave been estimated using data collected during the phase III efﬁ-
acy studies, and several vaccination programs including routine
accination at different ages completed or not by large catch-up
ampaigns have been investigated, supporting the beneﬁt which
ould be afforded by the vaccine.
Vaccination against dengue should also be considered as part
f a wider, integrated strategy with community involvement,
urveillance, case management, vector and outbreak control.
overnments will need to anticipate budget needs for routine
engue vaccination, catch-up programs, consumables, infrastruc-
ure, training, and surveillance. Alternative funding mechanisms
ay  be needed to ﬁnance vaccination programs in some countries
ocated in endemic zones.
The initial introduction of dengue vaccination will be accompa-
ied by phase IV studies that should be planned in collaboration
ith national authorities, and will serve to reinforce the medi-
al value (including effectiveness and safety), impact (e.g. indirect
ffect), and feasibility of vaccination. In particular, a Pharmacovigi-
ance Risk Management Plan (RMP) has been established to present
he strategy that Sanoﬁ Pasteur will deploy once the CYD dengue
accine is licensed and marketed in order to monitor and evaluate
dverse events associated with the use of CYD dengue vaccine, and
valuate vaccine effectiveness in real-life use. While no important
isks have been identiﬁed for CYD dengue vaccine during its clinical
evelopment in the target population, this plan has been designed
aking into consideration all clinical data including the observa-
ions outside the targeted age indication (below 9 years of age).
his action plan includes Post-Authorization Safety Studies (PASS)
nd Post-Authorization Effectiveness Studies (PAES) in addition to
he continuous follow-up of efﬁcacy studies (up to 5 years after last
ose injection).
. Conclusions
The data from the active phase of the two, pivotal, phase III efﬁ-
acy studies demonstrated that the CYD-TDV is efﬁcacious with a
atisfactory safety proﬁle, out to 25 months after the ﬁrst injec-
ion, and suggest that this vaccine can contribute to meet the WHO
bjectives to reduce by 2020 the dengue mortality by 50% and mor-
idity by 25%. The end of these active phases closes more than a
ecade of development of the CYD-TDV, although further follow
p, activities and efforts remain to deepen our understanding of
he vaccine, and also to prepare for the introduction and use of the
anoﬁ Pasteur dengue vaccine (Fig. 4). The observations made in
he ﬁrst years of the hospital phase of the efﬁcacy studies have con-
ributed to better deﬁne the target population (i.e. from 9 years of
ge), in order to drive the optimal public health impact through pro-
hylaxis, and the development of tools and actions taken to reach
hat goal. Dengue is a complex disease, and both short-term and
ong-term safety, and efﬁcacy will have to be considered further
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to assess the overall beneﬁt of the vaccine for human health. This
is ongoing and will continue to be addressed by long-term follow-
up and future post-licensure studies, with results available in the
coming years. Our predeﬁned risk management plan is designed to
conﬁrm our safety proﬁle in a real-world use setting after vaccine
implementation.
In conclusion, the development of a dengue vaccine, similar
to other recent vaccine successes against human papillomavirus
and pneumococcal disease, requires a long standing and contin-
uous effort from private and public organizations. In this regard,
we have in the past 22 years beneﬁted from multiple external col-
laborations across ﬁve continents. Since the very beginning, these
have been critical in developing a vaccine that might eventually
bring a solution to the still growing and worldwide problem pre-
sented by dengue [86,87]. Moving forward, there is a need for the
development of new models and collaborations in order to better
decipher the immunological mechanisms triggered by CYD-TDV.
One such example being the use of translational science models,
and in particular systems vaccinology approaches and tools [88].
Acknowledgements
The authors would like to thank all the investigators, children
and their parents who participated in the clinical studies evaluat-
ing CYD-TDV, all collaborators involved worldwide since 20 years
in the Sanoﬁ Pasteur dengue program, and all dengue experts with
whom contacts and collaborations were established (past, present
and future). The authors would also like to recognize all Sanoﬁ
Pasteur colleagues who  have supported the program.
Editorial assistance with the preparation of the manuscript
was provided by Richard Glover of inScience Communications,
Springer Healthcare, funded by Sanoﬁ Pasteur. The authors also
want to acknowledge Valentine Delore for critical reading of the
manuscript.
All authors are employees of Sanoﬁ Pasteur.
References
[1] Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical
development of YFV 17D-based chimeric vaccines against dengue, West Nile
and  Japanese encephalitis viruses. Vaccine 2010;28(3):632–49.
[2] Guy B, Barrere B, Malinowski C, Saville M,  Teyssou R, Lang J. From research to
phase III: preclinical, industrial and clinical development of the Sanoﬁ Pasteur
tetravalent dengue vaccine. Vaccine 2011;29(42):7229–41.
[3] Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P,
Suvannadabba S, et al. Protective efﬁcacy of the recombinant, live-attenuated,
CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, con-
trolled phase 2b trial. Lancet 2012;380(9853):1559–67.
[4] Capeding MR,  Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua
MN,  et al. Clinical efﬁcacy and safety of a novel tetravalent dengue vaccine in
healthy children in Asia: a phase 3, randomised, observer-masked, placebo-
controlled trial. Lancet 2014;384(9951):1358–65.
[5] Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM,  Cunha R, Deseda C, et al.
Efﬁcacy of a tetravalent dengue vaccine in children in Latin America. N Engl J
Med  2015;372(2):113–23.
[6] Thomas SJ. Preventing dengue – is the possibility now a reality? N Engl J Med
2015;372(2):172–3.
[7] Barban V, Girerd Y, Aguirre M,  Gulia S, Petiard F, Riou P, et al. High stability of
yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale
production. Vaccine 2007;25(15):2941–50.
[8] Pugachev KV, Guirakhoo F, Ocran SW,  Mitchell F, Parsons M, Penal C, et al. High
ﬁdelity of yellow fever virus RNA polymerase. J Virol 2004;78(2):1032–8.
[9] Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, Lang J, et al. Genetic stability
of  a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine
2011;29(38):6629–35.
10] Dubayle J, Vialle S, Schneider D, Pontvianne J, Mantel NOA, et al. Site-speciﬁc
characterization of envelope protein N-glycosylation on Sanoﬁ Pasteur’s
tetravalent CYD dengue vaccine. Vaccine 2015;33(11):1360–8.
11] Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M,  Zhang Z, et al. Replication
of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in
dendritic and hepatic cells. Am J Trop Med  Hyg 2005;72(1):74–81.
12] Deauvieau F, Sanchez V, Balas C, Kennel A, DE Montfort A, Lang J, et al. Innate
immune responses in human dendritic cells upon infection by chimeric yellow-
fever dengue vaccine serotypes 1-4. Am J Trop Med  Hyg 2007;76(1):144–54.
7 ne 33 
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[110 B. Guy et al. / Vacci
13] Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, et al. Differ-
ent  innate signatures induced in human monocyte-derived dendritic cells by
wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus,
or  attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis
2011;203(1):103–8.
14] Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M,  et al.
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and
protective in nonhuman primates. J Virol 2000;74(12):5477–85.
15] Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety
and  efﬁcacy of chimeric yellow Fever-dengue virus tetravalent vaccine formu-
lations in nonhuman primates. J Virol 2004;78(9):4761–75.
16] Guy B, Barban V, Mantel N, Aguirre M,  Gulia S, Pontvianne J, et al. Evaluation
of  interferences between dengue vaccine serotypes in a monkey model. Am J
Trop Med Hyg 2009;80(2):302–11.
17] Ravel G, Guy B, Mantel N, Lang J, Gould S. Sanoﬁ Pasteur live attenuated, tetrava-
lent  dengue vaccine toxicity, biodistribution and shedding study in cynomolgus
monkeys. Abstract 630. Am J Trop Med  Hyg 2012;87(5 Suppl 1):150–226.
18] Higgs S, Vanlandingham DL, Klingler KA, McElroy KL, McGee CE, Harring-
ton L, et al. Growth characteristics of ChimeriVax-Den vaccine viruses in
Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med  Hyg
2006;75(5):986–93.
19] Kazimirova M, Mantel N, Raynaud S, Slovak M,  Ustanikova K, Lang J, et al. Eval-
uation of chimeric yellow fever 17D/dengue viral replication in ticks. Vector
Borne Zoonotic Dis 2012;12(11):979–85.
20] Monath TP, Myers GA, Beck RA, Knauber M,  Scappaticci K, Pullano T, et al.
Safety testing for neurovirulence of novel live, attenuated ﬂavivirus vaccines:
infant mice provide an accurate surrogate for the test in monkeys. Biologicals
2005;33(3):131–44.
21] McGee CE, Lewis MG,  Claire MS,  Wagner W,  Lang J, Guy B, et al. Recombinant
chimeric virus with wild-type dengue 4 virus premembrane and envelope and
virulent yellow fever virus Asibi backbone sequences is dramatically attenuated
in  nonhuman primates. J Infect Dis 2008;197(5):693–7.
22] McGee CE, Tsetsarkin K, Vanlandingham DL, McElroy KL, Lang J, Guy B,
et  al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine
sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti
mosquitoes. J Infect Dis 2008;197(5):686–92.
23] McGee CE, Tsetsarkin KA, Guy B, Lang J, Plante K, Vanlandingham DL, et al.
Stability of yellow fever virus under recombinatory pressure as compared with
chikungunya virus. PLOS ONE 2011;6(8):e23247.
24] Lefeuvre A. Caractérisation des interactions entre les cellules hépatiques et les
souches sauvage et vaccinale du virus de la ﬁèvre jaune: application à l’étude
de  virus ﬁèvre jaune chimériques utilisés pour le développement d’un vaccin
contre la dengue. In: Diplôme de Doctorat 2005; Université Claude Bernard
Lyon 1, No 129. 2005.
25] Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue
S,  et al. Evaluation by ﬂow cytometry of antibody-dependent enhancement
(ADE) of dengue infection by sera from Thai children immunized with a live-
attenuated tetravalent dengue vaccine. Vaccine 2004;22(27–28):3563–74.
26] Morrison D, Legg TJ, Billings CW,  Forrat R, Yoksan S, Lang J. A novel tetravalent
dengue vaccine is well tolerated and immunogenic against all 4 serotypes in
ﬂavivirus-naive adults. J Infect Dis 2010;201(3):370–7.
27] Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetrava-
lent dengue vaccine in dengue-naive children, adolescents, and adults in
Mexico city: randomized controlled phase 1 trial of safety and immunogenicity.
Pediatr Infect Dis J 2011;30(1):e9–17.
28] Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-
attenuated, tetravalent dengue vaccine in children, adolescents and adults
in  a dengue endemic country: randomized controlled phase I trial in the
Philippines. Vaccine 2011;29(22):3863–72.
29] Qiao M,  Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue
and yellow fever vaccination on the immunogenicity, infectivity, and safety
of  a tetravalent dengue vaccine in humans. Am J Trop Med  Hyg 2011;85(4):
724–31.
30] Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, et al.
Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds
previously vaccinated against yellow fever: randomized, controlled, phase II
study in Piura, Peru. Vaccine 2012;30(41):5935–41.
31] Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, et al.
Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-
TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in
Singapore. Hum Vaccin Immunother 2012;8(9):1259–71.
32] Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, et al. Safety and
immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11
years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine
2013;31(49):5814–21.
33] Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live
attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine:
Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-
immunity in induction of cross neutralizing antibody responses to all 4 dengue
serotypes. Hum Vaccin 2006;2(2):60–7.
34] Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M,  et al. Cell-
mediated immunity induced by chimeric tetravalent dengue vaccine in naive
or  ﬂavivirus-primed subjects. Vaccine 2008;26(45):5712–21.
35] Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei
Liang A, et al. Persistence of Th1/Tc1 responses one year after tetravalent
[(2015) 7100–7111
dengue vaccination in adults and adolescents in Singapore. Hum Vaccin
Immunother 2013;9(11):2317–25.
36] Dayan G, Galán-Herrera G, Forrat R, Zambrano B, Bouckenooghe A, Haren-
berg A, et al. Assessment of bivalent and tetravalent dengue vaccine
formulations in ﬂavivirus-naïve adults in Mexico. Hum Vaccin Immunother
2014;10(10):2853–63.
37] European Medicines Agency. Guideline on quality, non-clinical
and clinical aspects of live recombinant viral vectored vaccines.
EMA/CHMP/VWP/141697/2009; 2010.
38] Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, et al.
Live  virus vaccines based on a yellow fever vaccine backbone: standard-
ized  template with key considerations for a risk/beneﬁt assessment. Vaccine
2015;33(1):62–72.
39] World Health Organization. Guidelines on the quality, safety and efﬁcacy of
dengue tetravalent vaccines (live, attenuated). Geneva: World Health Organi-
zation, WHO  Expert Committee on Biological Standardization; WHO  Technical
Report Series, No. 979 Annex 2 (Replacement of Annex 1 of WHO  Technical
Report Series, No. 932 adopted by ECBS in 2011. 2011. Available at: http://
www.who.int/biologicals/areas/vaccines/TRS 979 Annex 2pdf?ua=1).
40] Jackson N. Sanoﬁ Pasteur dengue vaccine. In: The American Society of Tropical
Medicine and Hygiene 63rd Annual Meeting, November 3rd Symposium 2014.
2014.
41] Hadinegoro SR, Arredondo-García JL, Capeding MR,  Deseda C, Chotpitaya-
sunondh T, Dietze R, et al. Efﬁcacy and long-term safety of a dengue vaccine in
regions of endemic disease. N Engl J Med  2015;373:1195–206.
42] Gamble J, Bethell D, Day NP, Loc PP, Phu NH, Gartside IB, et al. Age-related
changes in microvascular permeability: a signiﬁcant factor in the susceptibility
of  children to shock? Clin Sci (Lond) 2000;98(2):211–6.
43] Hanna-Wakim R, Yasukawa LL, Sung P, Fang M,  Sullivan B, Rinki M,  et al. Age-
related increase in the frequency of CD4(+) T cells that produce interferon-
gamma  in response to staphylococcal enterotoxin B during childhood. J Infect
Dis 2009;200(12):1921–7.
44] Jackson N, Boaz M, Hu B, Langevin E, Byers A, Baric R, et al. Investigations of the
observed efﬁcacy of the CYD tetravalent dengue vaccine in the phase 2b trial
in Ratchaburi, Thailand. Abstract 576. Am J Trop Med Hyg 2014;91(5 Suppl
1):149–228.
45] Guy B, Boaz M, Byers A, Saulnier A, de Silva A, Henein S, et al. Assessment
of the qualitative immune response induced by the CYD tetravalent dengue
vaccine in human volunteers. Abstract 575. Am J Trop Med Hyg  2014;91(5
Suppl 1):149–228.
46] Thomas SJ. Dengue human infection model: re-establishing a tool for under-
standing dengue immunology and advancing vaccine development. Hum
Vaccin Immunother 2013;9(7):1587–90.
47] Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW,  Green S, Ennis FA, et al.
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to
viremia and severity of disease in a prospective cohort study of DV infection in
Thailand. J Infect Dis 2004;189(6):990–1000.
48] Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B,
Klungthong C, et al. Dengue virus neutralizing antibody levels associated
with protection from infection in thai cluster studies. PLoS Negl Trop Dis
2014;8(10):e3230.
49] Timiryasova TM,  Bonaparte MI,  Luo P, Zedar R, Hu BT, Hildreth SW.  Opti-
mization and validation of a plaque reduction neutralization test for the
detection of neutralizing antibodies to four serotypes of dengue virus used
in  support of dengue vaccine development. Am J Trop Med  Hyg 2013;88(5):
962–70.
50] Rodrigo WW,  Alcena DC, Rose RC, Jin X, Schlesinger JJ. An automated Dengue
virus microneutralization plaque assay performed in human Fc{gamma}
receptor-expressing CV-1 cells. Am J Trop Med  Hyg 2009;80(1):61–5.
51] Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, et al. Compar-
ative evaluation of three assays for measurement of dengue virus neutralizing
antibodies. Am J Trop Med  Hyg 2008;79(1):115–22.
52] de Alwis R, de Silva AM.  Measuring antibody neutralization of dengue
virus (DENV) using a ﬂow cytometry-based technique. Methods Mol  Biol
2014;1138:27–39.
53] Byers A, Broder R, Moser J, Boaz M, Warren W,  Jackson N, et al. Serotype-speciﬁc
dengue neutralizing antibody responses in FcgR expressing CV1 cells. Abstract
833.  Am J Trop Med  Hyg 2014;91(5 Suppl 1):228–303.
54] Sabin AB. Research on dengue during World War  II. Am J Trop Med Hyg
1952;1(1):30–50.
55] Snow GE, Haaland B, Ooi EE, Gubler DJ. Review article: research on dengue
during World War  II revisited. Am J Trop Med  Hyg 2014;91(6):1203–17.
56] Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, Saborio S, et al. Trends
in  patterns of dengue transmission over 4 years in a pediatric cohort study in
Nicaragua. J Infect Dis 2010;201(1):5–14.
57] Endy TP, Anderson KB, Nisalak A, Yoon IK, Green S, Rothman AL, et al. Determi-
nants of inapparent and symptomatic dengue infection in a prospective study
of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis
2011;5(3):e975.
58] Anderson KB, Gibbons RV, Cummings DA, Nisalak A, Green S, Libraty DH, et al. A
shorter time interval between ﬁrst and second dengue infections is associated
with protection from clinical illness in a school-based cohort in Thailand. J
Infect Dis 2014;209(3):360–8.
59] Montoya M,  Gresh L, Mercado JC, Williams KL, Vargas MJ,  Gutierrez G, et al.
Symptomatic versus inapparent outcome in repeat dengue virus infections is
ne 33 
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[B. Guy et al. / Vacci
inﬂuenced by the time interval between infections and study year. PLoS Negl
Trop Dis 2013;7(8):e2357.
60] Olkowski S, Forshey BM,  Morrison AC, Rocha C, Vilcarromero S, Halsey ES, et al.
Reduced risk of disease during postsecondary dengue virus infections. J Infect
Dis 2013;208(6):1026–33.
61] Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S,
et  al. B-cell responses during primary and secondary dengue virus infections
in  humans. J Infect Dis 2011;204(10):1514–22.
62] Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, et al. Analysis of
cross-reactive antibodies recognizing the fusion loop of envelope protein and
correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS
Negl  Trop Dis 2013;7(9):e2451.
63] Tsai WY,  Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, et al. High-avidity
and potently neutralizing cross-reactive human monoclonal antibodies derived
from secondary dengue virus infection. J Virol 2013;87(23):12562–75.
64] Patel B, Sapparapu G, Crowe J, Baric R, de Silva A. Characterization of neutral-
izing antibody responses following natural secondary dengue virus infections.
Abstract 626. Am J Trop Med  Hyg 2014;91(5 Suppl 1):149–228.
65] Zompi S, Montoya M,  Pohl MO,  Balmaseda A, Harris E. Dominant cross-reactive
B  cell response during secondary acute dengue virus infection in humans. PLoS
Negl Trop Dis 2012;6(3):e1568.
66] Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM.
Preexisting neutralizing antibody responses distinguish clinically inapparent
and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect
Dis 2015;211(4):590–9.
67] Anders KL, Nguyet NM,  Chau NV, Hung NT, Thuy TT, Lien le B, et al. Epi-
demiological factors associated with dengue shock syndrome and mortality
in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med
Hyg 2011;84(1):127–34.
68] Guzman MG,  Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. Effect of age on
outcome of secondary dengue 2 infections. Int J Infect Dis 2002;6(2):118–24.
69] Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC,
et  al. Differences in dengue severity in infants, children, and adults in a 3-
year hospital-based study in Nicaragua. Am J Trop Med  Hyg 2005;73(6):
1063–70.
70] Ooi EE, Goh KT, Chee Wang DN. Effect of increasing age on the trend of dengue
and  dengue hemorrhagic fever in Singapore. Int J Infect Dis 2003;7(3):231–2.
71] Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and
tropical cytokine storms. Nat Rev Immunol 2011;11(8):532–43.
72] Weiskopf D, Angelo MA,  de Azeredo EL, Sidney J, Greenbaum JA, Fernando
AN, et al. Comprehensive analysis of dengue virus-speciﬁc responses sup-
ports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S
A  2013;110(22):E2046–53.
73] Zellweger RM, Eddy WE,  Tang WW,  Miller R, Shresta S. CD8+ T cells prevent
antigen-induced antibody-dependent enhancement of dengue disease in mice.
J  Immunol 2014;193(8):4117–24.74] Zellweger RM,  Miller R, Eddy WE,  White LJ, Johnston RE, Shresta S. Role of
humoral versus cellular responses induced by a protective dengue vaccine
candidate. PLoS Pathog 2013;9(10):e1003723.
75] Stephens HA. HLA and other gene associations with dengue disease severity.
Curr Top Microbiol Immunol 2010;338:99–114.
[
[(2015) 7100–7111 7111
76] Whitehorn J, Chau TN, Nguyet NM,  Kien DT, Quyen NT, Trung DT, et al. Genetic
variants of MICB and PLCE1 and associations with non-severe dengue. PLOS
ONE 2013;8(3):e59067.
77] Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, et al. Broad
neutralization of wild-type dengue virus isolates following immunization in
monkeys with a tetravalent dengue vaccine based on chimeric yellow fever
17D/dengue viruses. Virology 2012;429(2):91–8.
78] Gubler DJ, Ooi EE, Vasudevan S, editors. Dengue and Dengue Hemorrhagic
Fever. 2nd Edition. Wallingford, United Kingdom: CABI Publishing; 2014. ISBN-
10:  1845939646.
79] OhAinle M,  Balmaseda A, Macalalad AR, Tellez Y, Zody MC,  Saborio S, et al.
Dynamics of dengue disease severity determined by the interplay between
viral genetics and serotype-speciﬁc immunity. Sci Transl Med  2011;3(114),
114ra128.
80] Barban V, Mantel N, Harenberg A, De Montfort A, Charnay C, Jackson N, et al.
Protective immunity induced against DENV-2 intravenous challenge in non-
human primates immunized with CYD vaccine clinical lots. Abstract LB-3233.
In:  The American Society of Tropical Medicine and Hygiene 63rd Annual
Meeting 2014. 2014. http://www.abstractsonline.com/Plan/ViewAbstract.
aspx?sKey=52126352-c6f3-46f9-9c1f-c18e06fe67c4&cKey=d49492d8-
dcd8-4bab-b76b-a1e374fbb4c5&mKey=%7b52AE2426-7F12-4D2B-9404-
C0D0B5A8EB5A%7d.
81] de Alwis R, Smith SA, Olivarez NP, Messer WB,  Huynh JP, Wahala WM,  et al.
Identiﬁcation of human neutralizing antibodies that bind to complex epitopes
on  dengue virions. Proc Natl Acad Sci U S A 2012;109(19):7439–44.
82] Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, et al. The potent
and broadly neutralizing human dengue virus-speciﬁc monoclonal antibody
1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the
envelope protein. mBio 2013;4(6), e00873-913.
83] Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM,  Crowe Jr JE. Isolation
of  dengue virus-speciﬁc memory B cells with live virus antigen from human
subjects following natural infection reveals the presence of diverse novel func-
tional groups of antibody clones. J Virol 2014;88(21):12233–41.
84] Dejnirattisai W,  Wongwiwat W,  Supasa S, Zhang X, Dai X, Rouvinsky A, et al.
A  new class of highly potent, broadly neutralizing antibodies isolated from
viremic patients infected with dengue virus. Nat Immunol 2015;16(2):170–7.
85] Nguyet MN,  Duong TH, Trung VT, Nguyen TH,  Tran CN, Long VT, et al.
Host and viral features of human dengue cases shape the population of
infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A
2013;110(22):9072–7.
86] Bhatt S, Gething PW,  Brady OJ, Messina JP, Farlow AW,  Moyes CL, et al. The
global distribution and burden of dengue. Nature 2013;496(7446):504–7.
87] Guzman MG,  Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue:
a  continuing global threat. Nat Rev Microbiol 2010;8(12 Suppl):S7–16.
88] Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity 2010;33(4):
516–29.89] Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections.
Postgrad Med  J 2004;80:588–601.
90] WHO. Dengue guidelines for diagnosis, treatment, prevention and control;
2009. http://www.who.int/tdr/publications/documents/dengue-diagnosis.
pdf.
